Sign Out
Pharmacodynamics: An antagonist of alpha1-adrenoreceptor in the lower urinary tract. Blockage of these adrenoreceptors can cause smooth muscles in the bladder neck and prostate to relax, resulting in an improvement in urine flow rate and a reduction in BPH symptoms.
Pharmacokinetics: Absorption: Decrease 50% under fasting conditions.
Distribution: Vd: 3.2 L/kg.
Protein binding: 82% to 90%.
Metabolism: Hepatic, primarily via CYP3A4.
Bioavailability: 49% following a meal.
Half-life elimination: 10 hours.
Time to peak, plasma: 8 hours following a meal.
Excretion: Feces (69%); urine (24%; 11% as unchanged drug).
